DiaMedica Announces $30.1M Private Placement for DM199

Diamedica Therapeutics ( (DMAC) ) has shared an announcement.

On July 21, 2025, DiaMedica Therapeutics announced a $30.1 million private placement of common shares with existing accredited investors, expected to close by July 23, 2025. The funds will support the company’s preeclampsia clinical development program for DM199 and other corporate purposes, potentially accelerating their progress in developing treatments for conditions with no current approved options.

The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.

Spark’s Take on DMAC Stock

According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.

Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.

To see Spark’s full report on DMAC stock, click here.

More about Diamedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious ischemic diseases, including preeclampsia, fetal growth restriction, and acute ischemic stroke. Their lead candidate, DM199, is a recombinant form of the KLK1 protein, which is an established therapeutic modality in Asia for treating these conditions.

Average Trading Volume: 210,878

Technical Sentiment Signal: Hold

Current Market Cap: $179.3M

Learn more about DMAC stock on TipRanks’ Stock Analysis page.